Repligen Company (RGEN) named price of Common Stock Shares

Repligen Company (NASDAQ: RGEN) today announced the pricing of an underwritten public offering at a public offering price of $181 per share for 1.5 million shares of its common stock.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Repligen Company has also given the underwriters a 30-day chance to buy up to 225,000 additional common stock securities, fewer discounts, and commissions at the public bidding offer. Repligen estimates the revenue from the offering to be roughly around $271.5 million before deducting the underwriting discounts and fees and other offering costs, minus any exercise of the underwriters’ choice to buy additional stock. Subject to standard closing terms, the offering is scheduled to close on or around 10 December 2020.

Repligen Company plans to use the net proceeds from this sale for working capital and other general corporate needs. Net profits from this deal can also be used to support future sales or acquisitions in supplementary entities, goods, facilities, and technology. At this time, Repligen has not entered into any agreements or commitments about any acquisitions or investments.

These shares will be offered and distributed in compliance with the Securities and Exchange Commission (S.E.C.) and an immediately effective declaration of the shelf’s registration (including the base prospect), which had been previously submitted. A preliminary supplement to the prospectus related to this bid was submitted with the S.E.C. If available, copies of the final supplement to the prospectus and the accompanying prospectus relating to this offering can be obtained from J.P. Morgan Securities L.L.C.

Repligen Corporation is a global life sciences organization that produces and commercializes very advanced bioprocessing technologies and systems that improve biological drug production processes’ performance. Biopharmaceutical device manufacturers and contract production and processing companies (CDMOs) worldwide are our main clients.


Please enter your comment!
Please enter your name here